TP53 and neoplasm: In clinical practice, such classification relies on results of tumor immunohistochemistry for mismatch repair (MMR) proteins and p53 (the protein product of tumor suppressor gene TP53), as well as sequencing for hotspot mutations of the gene encoding for the enzyme DNA polymerase epsilon (POLE).